Professor Arjun Jayadev hails Indian Supreme Court rejection of patent protection for cancer drug

Harry Konstantinidis | April 22, 2013
Professor Arjun Jayadev

Professor Arjun Jayadev

On April 1, the Indian Supreme Court denied a request for patent protection for Gleevec, the cancer drug developed by Swiss pharmaceutical Novartis. 

In a recent article published in "Project Syndicate", Associate Professor of Economics Arjun Jayadev and Joseph E. Stiglitz, Professor of Economics at Columbia University and Nobel laureate, hail this decision as a very significant development not only in the fight against cancer, but also as a step towards freeing up resources for investments in education and poverty reduction across the developing world.

You can read the full article here.

Tags: arjun jayadev , economics , india , patents

Comment on this story

Comments (0)